Brain barrier-crossing conjugates enable the systemic delivery of large therapeutic molecules to the brain.
Credit: Lab of Yizhou Dong, PhD, at Icahn Mount Sinai
Credit: Lab of Yizhou Dong, PhD, at Icahn Mount Sinai
Researchers at the Icahn School of Medicine at Mount Sinai have developed an innovative approach—demonstrated in mouse models and isolated human brain tissue—to safely and effectively deliver therapeutics into the brain, providing new possibilities for treating a wide range of neurological and psychiatric diseases.
Published in the November 25 online issue of Nature Biotechnology, the study introduces a first-of-its-kind blood-brain barrier-crossing conjugate (BCC) system, designed to overcome the protective barrier that typically blocks large biomolecules from reaching the central nervous system (CNS).
